About Us

Targeted therapeutic innovation to improve health and quality of life

Our Vision

We aim to improve the health and quality of life of patients by creating high value therapeutics addressing global unmet medical needs.

Mironid® is a vibrant, growing, customer-centric company with an outstanding team motivated to deliver innovative new medicines.

Our Approach

Our mission is to become a world leader in cell signalling directed therapeutic development.

Mironid® is currently building and progressing a pipeline of early stage drug discovery programmes that are initially targeted at cAMP degrading phosphodiesterase enzymes. These will generate novel and differentiated therapies for a range of therapeutic indications

Current and Future Growth Ambitions

Engaging with patient groups
& charities to tackle hard-to-treat diseases

Engaging with patient groups
& charities to tackle hard-to-treat diseases

£4.3M ($6.2M) Series A, led by Epidarex Capital, completed in June 2016

Global leader in PDE
therapeutic development

Progress programmes to
development candidate status

Strong portfolio of clinical and preclinical stage assets

Accelerate assets to market
driven value inflection points

Supportive investors, world class board, management team & advisors

Series B Investment to move
assets in to clinical development

On track for IPO to extend & expand portfolio via in-house R&D, licensing & acquisitions

An ambitious, vibrant, growing, customer-centric company

get in touch